Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

6.600 +1.110 (+20.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Xeris (XERS) Q2 Revenue Jumps 49%
Via The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance
Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to... 
Via Chartmill
Topics Earnings
Earnings Scheduled For August 7, 2025
 
Via Benzinga
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria
XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score. 
Via Chartmill
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
 
Via Benzinga
Earnings Outlook For Xeris Biopharma Holdings
 
Via Benzinga
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template
XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick?
Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS). 
Via Chartmill
Xeris Biopharma - Possibly The Best Pharma Stock
The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. 
Via Talk Markets
Topics Stocks / Equities
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits
These stocks are gapping in today's session
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Earnings Scheduled For March 6, 2025
 
Via Benzinga
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
 
Via Benzinga
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
 
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
 
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and... 
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares. 
Via InvestorPlace
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement. 
Via InvestorPlace
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market. 
Via InvestorPlace
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.